SHPH · CIK 0001757499 · operating
Shuttle Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company's lead candidate is Ropidoxuridine, an oral halogenated pyrimidine in clinical development for brain tumors and sarcomas. The pipeline also includes multiple preclinical programs: SP-2-225, a candidate targeting immune system regulation; SP-1-303, a selective Class I histone deacetylase (HDAC) inhibitor being evaluated for estrogen receptor positive breast cancer; and SP-1-161, an HDAC inhibitor designed to activate mutated ATM response pathways.
The company was founded in 2012 and is incorporated in Delaware with headquarters in Gaithersburg, Maryland. Shuttle operates as a clinical-stage entity with minimal current revenue generation, maintaining a small organizational footprint of nine full-time employees. The company's operations are concentrated in the United States.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-3.30 | $-3.19 | -650.0% | |
| 2023 | $-0.44 | $-0.44 | -51.7% | |
| 2022 | — | $-0.29 | — |